Approval · Notice of Compliance 35535 · 2025
REZUROCK: Notice of Compliance 35535
Issued June 18, 2025
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 35535
- Date
- June 18, 2025
- Company
- Sanofi-Aventis Canada Inc.Toronto, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Change in the specification for the drug product
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| REZUROCK | Not yet assigned | — |
Medicinal ingredients
- BELUMOSUDIL MESYLATE 200 MG per TAB